WuXi AppTec has announced the sale of its clinical research assets for 2.8 billion yuan, with Hillhouse Capital as the buyer. The deal, disclosed on October 26, involves WuXi AppTec’s wholly-owned subsidiary Shanghai WuXi transferring medical assets to a newly established Hillhouse-affiliated private equity fund.

The company stated that the divestiture aligns with its strategy to focus on its CRDMO (Contract Research, Development, and Manufacturing Organization) model, emphasizing drug discovery, lab testing, and process development. Proceeds from the transaction will support global expansion and capacity deployment, reinforcing long-term growth objectives.

The announcement coincided with WuXi AppTec’s Q3 earnings report, which showed robust performance: revenue rose 18.61% year-on-year to 32.86 billion yuan, while net profit surged 84.84% to 12.08 billion yuan. Despite strong earnings, the decision to offload its clinical research business has raised questions about the rationale behind the move.

This marks WuXi AppTec’s second major divestment following last year’s sale of its U.S. cell and gene therapy unit (WuXi ATU). Similarly, Bristol-Myers Squibb (BMS) recently sold its stake in a China joint venture to Hillhouse. Industry observers note that rising R&D costs and global competition are prompting major pharma firms to streamline operations and refocus on core competencies.

The divested entities—Jin Shi Medical and Kantar Health—specialize in clinical research services, contributing less than 5% (1.81 billion yuan) to WuXi AppTec’s 2024 revenue. Financials reveal mixed performance: Kantar Health reported losses of 42.47 million yuan and 75.45 million yuan in 2024 and Q1–Q3 2025, respectively, while Jin Shi Medical posted declining profits.

WuXi AppTec emphasized that the sale allows deeper focus on high-growth CRDMO segments like oligonucleotides and peptides, which align with booming demand for next-gen therapies such as GLP-1 drugs. Meanwhile, Hillhouse’s acquisition spree—including the BMS deal—highlights its strategy to capitalize on pharma spin-offs.

Hillhouse, founded in 2005, has a track record of strategic healthcare investments, such as its 2017 purchase of Pfizer’s stake in Hisun-Pfizer (now Huanhui Pharma). The firm’s latest move underscores its confidence in unlocking value from clinical research assets amid industry realignment.